NOK 21.7
Key Takeaways
Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia,...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA
Target Price
The average target price of NAVA.OL is 36 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
